ReviewBMB reports2019
Recent advances in organoid culture for insulin production and diabetes therapy: methods and challenges.
Review in BMB reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Progress in experimental models to investigate the in vivo and in vitro antidiabetic activity of drugs.Animal models and experimental medicine · 2024Review
- Application and challenge of pancreatic organoids in therapeutic research.Frontiers in pharmacology · 2024Review
- Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus.Stem cell reviews and reports · 2023Review
- Review
- High-throughput formation and image-based analysis of basal-in mammary organoids in 384-well plates.Scientific reports · 2022Article
- Progressing Towards a Human-Centric Approach in Cancer Research.Frontiers in oncology · 2022Review
- Review
- A pancreas tumor derived organoid study: from drug screen to precision medicine.Cancer cell international · 2021Review
- Diabetes through a 3D lens: organoid models.Diabetologia · 2020Review
- The challenge of developing human 3D organoids into medicines.Stem cell research & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breakthroughs in stem cell technology have contributed to disease modeling and drug screening via organoid technology. Organoid are defined as three-dimensional cellular aggregations derived from adult tissues or stem cells. They recapitulate the intricate pattern and functionality of the original tissue. Insulin is secreted mainly by the pancreatic β cells. Large-scale production of insulin-secreting β cells is crucial for diabetes therapy. Here, we provide a brief overview of organoids and focus on recent advances in protocols for the generation of pancreatic islet organoids from pancreatic tissue or pluripotent stem cells for insulin secretion. The feasibility and limitations of organoid cultures derived from stem cells for insulin production will be described. As the pancreas and gut share the same embryological origin and produce insulin, we will also discuss the possible application of gut organoids for diabetes therapy. Better understanding of the challenges associated with the current protocols for organoid culture facilitates development of scalable organoid cultures for applications in biomedicine. [BMB Reports 2019; 52(5): 295-303].
Indexed as
Identifiers
30940326PMC6549913W2947122442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.